CG Oncology, Inc.
CGON
$42.61
$1.243.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -5.97% | 14.07% | |||
| Gross Profit | 11.29% | -14.28% | |||
| SG&A Expenses | 34.03% | 17.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.32% | 15.35% | |||
| Operating Income | -4.90% | -15.49% | |||
| Income Before Tax | -5.75% | -20.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.75% | -20.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.75% | -20.24% | |||
| EBIT | -4.90% | -15.49% | |||
| EBITDA | -4.38% | -15.18% | |||
| EPS Basic | -5.04% | -20.19% | |||
| Normalized Basic EPS | -5.03% | -20.21% | |||
| EPS Diluted | -5.04% | -20.19% | |||
| Normalized Diluted EPS | -5.03% | -20.21% | |||
| Average Basic Shares Outstanding | 0.66% | 0.05% | |||
| Average Diluted Shares Outstanding | 0.66% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||